Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer

BMC Cancer

Volumn 9, Issue , 2009, Pages 287-

  Wang, Qi ^a,e   Shen, Jing ^a   Li, Zhen Fu ^a   Jie, Jian Zheng ^b   Wang, Wen Yue ^b   Wang, Jin ^c   Zhang, Zhong Tao ^c   Li, Zhi Xia ^d   Yan, Li ^a   Gu, Jin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER RECURRENCE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEOMICS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION STUDY;

AGED; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; PROTEOMICS; RETROSPECTIVE STUDIES; SERUM; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 70349850338     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-287     Document Type: Article

References (31)

1. Fang-ying X, Jian-kang D, Yi-min Z, Mei-juan Q, Fen-juan W, Yi-sen J, Guoping R, Maode L. Study on independent factors on the prognosis of colorectal carcinoma: TNM stage, tumor budding, perineural invasion, peritumoral lymphocytic infiltration and urine glucose. Chin J Epidemiol 2005, 26:366-369.
2. Watkins B, Szaro R, Ball S, Knubovets T, Briggman J, Hlavaty JJ, Kusinitz F, Stieg A, Wu YY. Detection of early-stage cancer by serum protein analysis. American Laboratory 2001, 33:32-36.
3. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin Chem 2001, 47:624-630.
4. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, Topolcan O. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003, 39:718-727. 10.1016/S0959-8049(02)00811-0, 12651195.
5. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult blood test. Lancet 1996, 348:1467-1471. 10.1016/S0140-6736(96)03430-7, 8942774.
6. Paszat SL, Berger BM. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol 2008, 103:2862-2870. 10.1111/j.1572-0241.2008.02088.x, 18759824.
7. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, Knigge K, Lance MP, Burgart LJ, Hamilton SR, Allison JE, Lawson MJ, Devens ME, Harrington JJ, Hillman SL. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008, 149:441-450.
8. Smith RA, Mettlin CJ, Davis KJ, Eyre H. American cancer society guidelines for the early detection of cancer. CA Cancer J Clin 2000, 50:34-49. 10.3322/canjclin.50.1.34, 10735014.
9. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-575. 10.1016/S0140-6736(02)07746-2, 11867112.
10. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002, 62:3609-3614.
11. Bañez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam BL, McLeod DG, Moul JW, Srivastava S. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003, 170:442-446. 10.1097/01.ju.0000069431.95404.56, 12853795.
12. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002, 48:1296-1304.
13. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright GL. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001, 158:1491-1502. 1891900, 11290567.
14. Poon TC, Yip TT, Chan AT, Christine Y, Victor Y, Tony SK, Lee CC, Leung TW, Ho SK, Johnson PJ. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003, 49:752-760. 10.1373/49.5.752, 12709366.
15. Ward DG, Cheng Y, N'Kontchou G, Thar TT, Barget N, Wei W, Billingham LJ, Martin A, Beaugrand M, Johnson PJ. HCC induced changes in the serum proteome of hepatitis C infected chronic liver disease patients. Br J Cancer 2006, 94:287-292. 10.1038/sj.bjc.6602923, 16404431.
16. Honda K, Hayashida Y, Umaki T, Takuji O, Tomoo K, Satoru K, Endo M, Tsuchida A, Aoki T, Itoi T, Moriyasu F, Hirohashi S, Yamada T. Possible Detection of Pancreatic Cancer by Plasma Protein Profiling. Cancer Res 2005, 65:10613-10622. 10.1158/0008-5472.CAN-05-1851, 16288055.
17. Chen YD, Zheng S, Yu JK, Hu X. Artificial neural networks analysis of surfaceenhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res 2004, 10:8380-8385. 10.1158/1078-0432.CCR-1162-03, 15623616.
18. Albrethsen J, Bøgebo R, Gammeltoft S, Olsen J, Winther B, Raskov H. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 2005, 5:8. 10.1186/1471-2407-5-8, 548152, 15656915.
19. Liu XP, Shen J, Li ZF, Yan L, Gu J. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Cancer Invest 2006, 24:747-753. 10.1080/07357900601063873, 17162557.
20. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-1061. 10.1093/jnci/93.14.1054, 11459866.
21. Timms JF, Arslan-Low E, Gentry-Maharaj A, Zhiyuan L, Vladimir DT, Podust N, Ford J, Fung ET, Gammerman A, Jacobs I, Menon U. Preanalytic Influence of Sample Handling on SELDI-TOF Serum Protein Profiles. Clinical Chemistry 2007, 53:645-656. 10.1373/clinchem.2006.080101, 17303688.
22. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJ, Johnson PJ, Martin A. Identification of serum biomarkers for colon cancer by proteomic analysis. British Journal of Cancer 2006, 94:1898-1905. 10.1038/sj.bjc.6603188, 16755300.
23. Hara T, Honda K, Ono M, Naito K, Hirohashi S, Yamada T. Identification of two serum biomarkers of renal cell carcinoma by surface-enhanced laser desorption/ionization mass spectrometry. J Urol 2005, 174:1213-1217. 10.1097/01.ju.0000173915.83164.87, 16145372.
24. Hammoud ZT, Dobrolecki L, Kesler KA, Rahmani E, Rieger K, Malkas LH, Hickey RJ. Diagnosis of Esophageal Adenocarcinoma by Serum Proteomic Pattern. Ann Thorac Surg 2007, 84:384-392. 10.1016/j.athoracsur.2007.03.088, 17643604.
25. Grizzle W, Semmes O, Bigbee W, Zhu L, Malik G, Oelschlager D. The need for review and understanding of SELDI-MALDI mass spectrometry data prior to analysis. Cancer Informatics 2005, 1:86-97.
26. Diamandis EP. Analysis of Serum Proteomic Patterns for Early Cancer Diagnosis: Drawing Attention to Potential Problems. J Natl Cancer Inst 2004, 96:353-356.
27. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005, 5:142-149. 10.1038/nrc1550, 15685197.
28. Ransohoff DF. Lessons from controversy: overian cancer screening and serum proteomics. J Natl Cancer Inst 2005, 97:315-319.
29. McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ. SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer. Clin Chem 2008, 54:53-60. 10.1373/clinchem.2007.091496, 18024530.
30. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005, 51:102-112. 10.1373/clinchem.2004.038950, 15613711.
31. McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ. Analytical Validation of Serum Proteomic Profiling for Diagnosis of Prostate Cancer: Sources of Sample Bias. Clin Chem 2008, 54:44-52. 10.1373/clinchem.2007.091470, 17981926.